CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

• Drug: CP-751,871
  

  CP-751,871 was given intravenously [IV] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.

  Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year).

• Drug: Docetaxel
  
  Docetaxel up to 75 mg/m^2 was administered intravenously [IV] on Day 1 of each 3-week dosing cycle.

Inclusion Criteria:

• Age greater than 18 years
• Documented advanced-stage non-hematologic malignancy for whom docetaxel monotherapy is a reasonable treatment option
• Eastern Cooperative Oncology Group [ECOG] performance status 0-1

Exclusion Criteria:

• Significant active cardiac disease
• Chemotherapy, biological or investigational agents within 4 weeks prior to dosing
• Inadequate bone marrow, renal, cardiac or liver function